NYSE:NVOPharmaceuticals
Oral Wegovy And Cancer Signals Reframe Novo Nordisk GLP 1 Opportunity
EMA committee issues positive opinion on EU marketing authorisation for oral Wegovy (semaglutide) for weight management, including cardiovascular outcomes.
Oral Wegovy would extend Novo Nordisk’s (NYSE:NVO) GLP-1 franchise beyond injectable formats.
New observational studies link GLP-1 drugs, including Ozempic, with reduced cancer progression and recurrence.
Together, these developments add fresh regulatory and scientific momentum to Novo Nordisk’s obesity and diabetes portfolio.
Novo...